🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for NK/T Cell Lymphoma Nos

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies NCT04329728Phase 1, Phase 211 sites📍 Duarte📍 Los Angeles📍 Los Angeles AVM Biotechnology Inc · Tests: AVM0703 A Prospective Clinical Study on Reduced-intensity Radiotherapy for Stage I/II Low-risk Nasal-type NK/T-cell Lymphoma Achieving Complete Remission After Chemotherapy NCT07628738Phase 21 site📍 Shanghai Ruijin Hospital · Tests: reduced-intensity radiotherapy Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma NCT04803201Phase 296 sites📍 Little Rock📍 Duarte📍 La Jolla Alliance for Clinical Trials in Oncology · Tests: Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Etoposide JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas NCT06716658Phase 22 sites📍 Tianjin📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: JAK1 Inhibitor Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE NCT01555892Phase 13 sites📍 Houston📍 Houston📍 Houston Baylor College of Medicine · Tests: EBV-specific T cells: A, EBV-specific T cells: B Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma NCT06314334Phase 27 sites📍 Fuzhou📍 Nantong📍 Shanghai Fudan University · Tests: Sintilimab+Pegaspargase, P-GemOx, GELAD, IMRT Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma NCT07502768Phase 1, Phase 21 site📍 Shanghai Rong Tao · Tests: Tislelizumab, Zeprumetostat Personalized NK Cell Therapy in CBT NCT02727803Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative Diseases NCT07727083n/a1 site📍 Shanghai Rong Tao Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma NCT07164560Phase 11 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: Anti-TRBC1 CAR-T cells CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia NCT06696846Phase 11 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: CD70 CAR-NK A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs) NCT07465835Phase 16 sites📍 New Haven📍 Atlanta📍 Grand Rapids Electra Therapeutics Inc. · Tests: ELA026 Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma NCT03719105EARLY Phase 16 sites📍 Birmingham📍 Orange📍 San Francisco New York Medical College · Tests: Methotrexate, pralatraxate,, Ifosfamide, Dexamethasone, Etoposide A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma NCT07000617Phase 23 sites📍 Beijing📍 Beijing📍 Beijing Peking University Cancer Hospital & Institute · Tests: DAPT regimen plus radiotherapy A Study of Ruxolitinib and Duvelisib in People With Lymphoma NCT05010005Phase 19 sites📍 Miami📍 Boston📍 Basking Ridge Memorial Sloan Kettering Cancer Center · Tests: Ruxolitinib, Duvelisib Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances NCT05092451Phase 1, Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Cyclophosphamide, CAR.70/IL15-transduced CB-NK cells, Fludarabine phosphate Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies NCT06909474Phase 11 site📍 Wuhan Chongqing Precision Biotech Co., Ltd · Tests: Anti-CD5 CAR NK cells Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma NCT06376721Phase 1, Phase 21 site📍 Beijing Beijing Tongren Hospital · Tests: Linperlisib, Camrelizumab, Pegaspargase, Dexamethasone Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas NCT02859402Phase 22 sites📍 Busan📍 Daegu Keimyung University Dongsan Medical Center · Tests: Busulfan, Fludarabine PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas NCT06530550Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: PI3K inhibitor Novel Therapeutic Approach for Human T-cell Malignancies NCT06600568n/a2 sites📍 Naples📍 Padova Istituto Oncologico Veneto IRCCS · Tests: Translation analysis RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies NCT06732492Phase 11 site📍 Wuhan Union Hospital, Tongji Medical College, Huazhong University… · Tests: RD13-02 cell infusion Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma NCT07162012EARLY Phase 11 site📍 Shanghai Shanghai General Hospital, Shanghai Jiao Tong University Sc… · Tests: EBV TCR-T Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma NCT02974647Phase 210 sites📍 Miami📍 Chicago📍 Boston Memorial Sloan Kettering Cancer Center · Tests: Ruxolitinib Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma NCT03501576n/a2 sites📍 Atlanta📍 Atlanta Emory University · Tests: Inactivated Influenza Vaccine A Registry for People With T-cell Lymphoma NCT05978141n/a26 sites📍 Duarte📍 San Diego📍 San Francisco Memorial Sloan Kettering Cancer Center · Tests: Optional Blood Sample and Nail Sample Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma NCT06824883Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: Immunochemotherapy PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL NCT07380984Phase 21 site📍 Shanghai Ruijin Hospital · Tests: PD-1 antibody, radiotherapy, Chidamide, golidocitinib Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma NCT03011814Phase 1, Phase 24 sites📍 Duarte📍 New York📍 Philadelphia City of Hope Medical Center · Tests: Durvalumab, Laboratory Biomarker Analysis, Lenalidomide Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type NCT05477264Phase 21 site📍 Seoul Won Seog Kim · Tests: Tislelizumab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy